Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...

The University hospitals of Geneva (HUG), the Department of Health and Mobilities (DSM) of the Canton of Geneva and the Wyss Center for Bio and Neuro Engineering enter into a three-party agreement to ...

“We’re continuing to innovate and evolve our precision neuromodulation therapy to provide the most effective and efficient treatment for patients,” said Giacomo Koch, MD, PhD, Sinaptica ...

Valencia Technologies announced today that it received a strategic investment totaling up to $35 million and appointed a new ...

Salvia BioElectronics has reported the first patient implanted with its ultra-thin implant for chronic migraine in The ...

aiming to augment patient outcomes during and between ketamine and neuromodulation therapies. The collaboration introduces a blend of neurological treatments and guided mindset support ...

The study will evaluate Sinaptica’s SinaptiStim in delivering simultaneous transcranial magnetic and alternating current ...

The cardiovascular portfolio grew mid-single-digits, with cardiac ablation solutions reporting 22% growth, driven by the Pulse Field Ablation (PFA) products, Affera and PulseSelect. Management ...

New research provides the first direct evidence that brain lesions causing secondary psychosis map to a common brain circuit ...

This significant influx of capital will empower Newronika to expand the clinical validation and commercialization of its ...